Global Blood Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Global Blood Therapeutics Inc (GBT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Global Blood Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 235M vs 80M combined for its competitors (74.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+21.9% annualized vs trailing 12 months), vs decelerating (-38.1%) for its tracked peer group.
- Growth: Global Blood Therapeutics Inc generated 50.5% revenue growth year over year in Q2 2022, vs 220.3% for its competitors combined.
- Profitability: Its -115.3% net margin compares with -535.6% for the peer group.
- Peer revenue share: Global Blood Therapeutics Inc accounted for 85.2% of combined revenue among its tracked peer group, down from 92.5% a year earlier.
- Peer differentiation: Revenue per employee of $0.43M compares with $0.15M for the peer group (2.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GBT Sales vs. its Competitors, Q2 2022
Global Blood Therapeutics Inc reported revenue growth of 50.46 % year on year in Q2 2022, below its competitors' combined revenue growth of 220.31 %.
With a net margin of -115.26 %, Global Blood Therapeutics Inc achieved higher profitability than its competitors (-535.62 %).
Global Blood Therapeutics Inc generated 85.18 % of the combined sales of its peer group, down from 92.45 % a year earlier.
API endpoints for this dataset
Global Blood Therapeutics Inc vs. its Competitors, Q2 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Global Blood Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Global Blood Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Global Blood Therapeutics Inc. | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (126) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Global Blood Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 50.5% for Global Blood Therapeutics Inc. Global Blood Therapeutics Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Global Blood Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Global Blood Therapeutics Inc. | - | Yes | Yes | No |
| Competitors combined (4) | ||||
| High-Confidence Competitors (138) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GBT Stock Performance relative to its Competitors
GBT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Contextlogic Inc | 282.9% | Outperformed |
| 2 | Editas Medicine Inc | 282.9% | Outperformed |
| 3 | Chemomab Therapeutics Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Global Blood Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Global Blood Therapeutics Inc.
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Global Blood Therapeutics Inc. |
4,492.59 | 234.86 |
 Contextlogic Inc |
692.92 | 15.73 |
 Chemomab Therapeutics Ltd |
673.50 | - |
 Editas Medicine Inc |
306.59 | 47.01 |
 Sigilon Therapeutics Inc |
56.22 | 17.65 |
| SUBTOTAL | 6,221.81 | 315.25 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Global Blood Therapeutics Inc. versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Global Blood Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Global Blood Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicycle Therapeutics Plc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Sanofi | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Takeda Pharmaceuticals | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Biontech Se | Company report | 85% |
| Novavax inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Verastem Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Cingulate Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Neonc Technologies Holdings Inc | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Valneva Se | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Ladrx Corporation | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| NAYA | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Heron Therapeutics Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Triple G | Company report | 85% |
| INVO | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| ENTO | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Curevac N v | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Kyowa Kirin | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Crinetics Pharmaceuticals Inc | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Acrotech Biopharma | Company report | 85% |
| Bioatla Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| Bonk Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| BMS | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Avenir Wellness Solutions Inc | Company report | 85% |
| Celgene | Company report | 85% |
| Inflarx N V | Company report | 85% |
| SHOT | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Therapeuticsmd Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Beyondspring Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Janssen Biotech | Company report | 85% |
| RENB | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Dermata Therapeutics Inc | Company report | 85% |
| Protara Therapeutics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Curis Inc | Company report | 85% |
| Geovax Labs Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Relmada Therapeutics Inc | Company report | 85% |
| Vbi Vaccines Inc | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Matinas Biopharma Holdings Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Range Impact Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Evofem Biosciences Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Tonix Pharmaceuticals Holding Corp | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Zyversa Therapeutics Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Organon and Co | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Sarepta Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Dr Reddy s Laboratories Limited | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Revolution Medicines Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Lianbio | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Arcturus Therapeutics Holdings Inc | Company report | 85% |
| Ionis Pharmaceuticals Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Roivant Sciences Ltd | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
Company report basis, confidence, active dates and source counts for Global Blood Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Global Blood Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Editas Medicine Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Global Blood Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Global Blood Therapeutics Inc. | 4,493 | 434,928 | -597,152 |
| Contextlogic Inc | 693 | 39,330 | 128,500 |
| Chemomab Therapeutics Ltd | 674 | - | -749,583 |
| Editas Medicine Inc | 307 | 540,287 | -849,989 |
| Sigilon Therapeutics Inc | 56 | 802,455 | -1,374,545 |
| PEERS TOTAL | 1,729 | 154,301 | -118,587 |
Global Blood Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 98.10 % | 37.89 % (avg) | +60.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.23 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.83 % | 7.58 % (avg) | -6.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Global Blood Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 10.1x | 4.3x | +5.9x |
| Return on Equity | -170.37 % | industry aggregate | -188.99 % |
| Return on Invested Capital | -32.27 % | -9.83 % (avg) | -22.44 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Global Blood Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | - | - | 57.31 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -21.56 % | -21.70 % | -31.09 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Global Blood Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.83 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Global Blood Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Global Blood Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+21.9% annualized vs trailing 12 months).
Weaknesses
- Return on equity 189.0 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-38.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Global Blood Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Global Blood Therapeutics Inc. | 5.14 | 7.79 | 2.50 |
| Contextlogic Inc | 7.54 | 18.49 | 0.25 |
| Chemomab Therapeutics Ltd | 5.12 | 9.08 | - |
| Editas Medicine Inc | 2.86 | 3.18 | 1.52 |
| Sigilon Therapeutics Inc | 1.17 | 2.28 | 0.39 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Global Blood Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Global Blood Therapeutics Inc. | Q2 2022 | +50.5 % | - |
| Contextlogic Inc | Q2 2026 | - | - |
| Chemomab Therapeutics Ltd | Q4 2025 | - | - |
| Editas Medicine Inc | Q2 2026 | +232.3 % | - |
| Sigilon Therapeutics Inc | Q2 2023 | +104.6 % | - |
| PEERS TOTAL | +127.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Global Blood Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Global Blood Therapeutics Inc. | Q2 2022 | +88.9 % | -51.4 % |
| Contextlogic Inc | Q2 2026 | - | - |
| Chemomab Therapeutics Ltd | Q4 2025 | -5.6 % | - |
| Editas Medicine Inc | Q2 2026 | - | - |
| Sigilon Therapeutics Inc | Q2 2023 | - | +27.5 % |
Global Blood Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Global Blood Therapeutics Inc. | - | - | - |
| Contextlogic Inc | 8.00% | 6.17% | 11.74% |
| Chemomab Therapeutics Ltd | - | - | - |
| Editas Medicine Inc | - | - | - |
| Sigilon Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Global Blood Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Global Blood Therapeutics Inc. | - | 19.13 |
| Contextlogic Inc | 0.66 | 44.04 |
| Chemomab Therapeutics Ltd | 73.33 | - |
| Editas Medicine Inc | - | 6.52 |
| Sigilon Therapeutics Inc | - | 3.18 |
| PEERS AVERAGE | - | 19.74 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.